Skip to main content

News

February 08, 2020
Intraoperative molecular imaging used to illuminate and target non-small-cell lung cancer shows improved outcomes for 26% of patients in multi-institutional Phase 2 clinical trial. WEST LAFAYETTE, Ind.
March 07, 2019
The researchers undertook the study to better understand oncologic and toxicity outcomes from a combined approach to treatment.
February 28, 2019
Patients with advanced biliary tract cancer may potentially be treated with tremelimumab in combination with microwave ablation, according to a pilot study.
February 26, 2019
Researchers assessed the efficacy and safety of Y-90 in 33 patients with metastatic pancreatic adenocarcinoma.
February 22, 2019
DOSIsoft, leading provider of advanced software solutions for Radiation Oncology and Nuclear Medicine, is pleased to announce it has received on March 7th, 2019, from the US Food and Drug Administration (FDA), the 510(k) clearance to market PLANET® …
February 21, 2019
To investigate the feasibility of SABR, investigators prospectively recruited 147 patients with oligometastatic cancer to the study.
February 14, 2019
Researchers have developed a prognostic score that can help to stratify candidates for transarterial chemoembolization (TACE), according to a study published in the Journal of Hepatology.
February 12, 2019
Patients with hepatocellular carcinoma and gross vascular invasion may have improved overall survival after being treated with dual modality radiation with external beam radiation therapy (EBRT) and transarterial radioembolization (TARE).
February 07, 2019
Results of a phase II trial suggest that image-guided high-dose-rate (HDR) brachytherapy (iBT) may lead to better outcomes than conventional transarterial embolization (cTACE) in treating unresectable hepatocellular carcinoma (HCC).
February 04, 2019
Patients with renal cell carcinoma who were treated with a combination of sorafenib and cryoablation were compared with those who were treated with sorafenib alone.
January 25, 2019
Primary malignant tumors comprise only 1% to 2% of childhood cancers, but alternatives are still needed for patients in whom chemotherapy fails.
Back to Top